• Mission
  • Leadership
  • Approach
  • Research
  • Pipeline
  • FAQ
  • Careers
  • News

Mission

Who we are

The Bill & Melinda Gates Medical Research Institute is a non-profit organization dedicated to the development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.

The institute works through collaborating partners and organizations, coordinating and driving the full spectrum of biopharmaceutical development activities, including pre-clinical development, full clinical development (from phase 1 through phase 3) and global regulatory interactions.

what we do

The institute focuses on programs aimed at reducing the burden of TB, malaria, diarrheal diseases, and maternal, newborn, and child illnesses.

As an affiliate of the Bill & Melinda Gates Foundation, the institute’s programs are focused on disease and health areas of primary focus at the foundation. The interventions under study and development are derived from sources both within and external to the foundation.

Approach

How We Work

Scientific discovery followed by product development and delivery is one formula for saving lives. It has turned HIV from a death sentence into a disease people can live with. It turned smallpox into a disease no one has to live with.

Right now, scientists know more about human biology than they ever have before. They have the computing power to simulate complex biological processes, and to do it incredibly quickly. The universe of the possible keeps expanding.

However, the necessary funding, tools and commitment have only rarely been brought together to serve the needs of the world’s poorest people. It’s time to use the latest innovations to improve all lives. We will combine advances in biomarker profiling of the immune system and infectious organisms and bioassays, quantitative sciences and statistical computing, and expertise in chemistry and manufacturing to move potential solutions from the laboratory into human trials.

We are part of a large community with shared goals, and we know we will reach those goals faster together. We rely on academic researchers, biotechnology and pharmaceutical companies, and global health organizations as partners in our work. We will share what we learn with our partners to accelerate the cycle of innovation.

Research

Priorities

  • Malaria
  • Tuberculosis
  • Diarrheal Disease
  • Maternal, Newborn, and Child Health
Eradicate malaria

Malaria may have killed half the people who have ever lived1. Every year, it kills almost 500,000 people and makes more than 200 million sick. As we drive toward zero deaths and zero cases, we will need a next-generation vaccine and drugs that combat resistance. See diagram attributions.

Accelerate the end of tuberculosis

Tuberculosis is currently the leading cause of death from infectious disease2. The treatment regimen we use today is long and complicated, and hundreds of thousands of cases are resistant to the standard drugs. To control the disease, we need a shorter, simpler course of treatment that works for both drug-sensitive and drug-resistant TB. Eventually, we need an effective vaccine. See diagram attributions.

End diarrheal deaths

Diarrhea is the second leading cause of death among children3. Virtually all those deaths occur in low-income countries. A recently developed vaccine for rotavirus, once the leading cause of diarrhea, has started to reduce mortality. Now, we need to tackle diarrhea's many other causes. See diagram attributions.

Improve outcomes in maternal and newborn child health

Globally, more than 2 million babies are still-born every year, and a similar number of babies die within the first month of life. Preterm birth is a major contributor to neonatal deaths, and many preterm babies die because their lungs are not ready for life outside the womb. Provision of antenatal corticosteroids and supplementation of lung surfactant have the potential to save many babies born prematurely. See diagram attributions.

Pipeline

 Preclinical


MRI TBD05 (SPR720)
MRI TBD01 (Sutezolid)
MRI EDV01 (Shigella Synthetic Conjugate Vaccine)
MRI MND01 (Dry Powder Lung Surfactant)
MRI RSM01 (RSV mAb)

 Phase 1

 Phase 2/3


MRI TBV02
(M72/ASO1)
MRI TBV01-201
(BCG REVAX)
TBD06
(TB Drug Regimen)
MRI TBD03-201
(TBA 7371)
TUBERCULOSIS
MALARIA
DIARRHEAL DISEASES
MATERNAL, NEWBORN, AND CHILD HEALTH
RESPIRATORY SYNCYTIALVIRUS
TUBERCULOSIS
MALARIA
DIARRHEAL DISEASES
MATERNAL, NEWBORN, AND CHILD HEALTH
RESPIRATORY SYNCYTIALVIRUS

Malaria, diarrheal diseases, and tuberculosis kill five people every minute.4

We believe we can help end this crisis.

Our bottom line is lives saved.

Gates MRI

FAQ

What is the relationship between the Gates MRI and the Bill & Melinda Gates Foundation?

  • The Gates MRI is subsidiary of the Bill & Melinda Gates Foundation funded by a grant from the foundation.
  • The Gates MRI is aligned with the vision of the Bill & Melinda Gates Foundation and guided by the belief that all lives have equal value.
Where is the Gates MRI located?

The Gates MRI is headquartered in Cambridge, Massachusetts.

Where can I find more information or inquire about job opportunities?

Further information about job opportunities and other updates about the Gates MRI can be found on the organization's careers page. If you would like to submit your resume to our human resources department, please send to [email protected]

How large is the Gates MRI? How many employees does Gates MRI have?

The Gates MRI plans on operating as a fully integrated, non-profit biotech organization staffed appropriately to advance a pipeline of programs in the prioritized disease areas from pre-clinical testing through human proof of concept studies. We expect we will scale up to 80 to 120 full-time employees over the next several years.

Does the Gates MRI provide research grants?

No, the Gates MRI is a non-profit biotech organization focused on accelerating product development for diseases that affect the world’s poorest populations. We do not anticipate making grants at this time.

Does the Gates MRI accept donations?

The Gates MRI does not solicit donations from the public. We are proud of our mission to develop products to fight malaria, tuberculosis, and diarrheal diseases, and encourage people who share our passion for saving lives to donate to causes aligned with their values.

What is the distinction between the Gates MRI and the Coalition for Epidemic Preparedness Innovations (CEPI)?

CEPI is focused on accelerating the development of vaccines for emerging infectious diseases. The Gates MRI will focus on developing interventions to fight persistent epidemics, such as malaria, tuberculosis, and enteric and diarrheal diseases.

Do you have a pool of product candidates to research? What is the Gates MRI pipeline of programs?

The team at Gates MRI is currently evaluating a number of products under development with foundation partners. Once this analysis is completed, we will share the pipeline.

How will the Gates MRI share its findings?

The Gates MRI will adhere to the foundation’s global access and open access policies.

  • Global Access, a core value of the foundation, rests on two principles: (a) prompt and broad dissemination of knowledge and information; and (b) access to products at an affordable price to people most in need. Gates MRI will manage our research activities in accordance with Global Access to ensure impact for its intended beneficiaries.
  • Open Access enables unrestricted access and reuse of all peer-reviewed published research that has been funded by the foundation, including underlying data sets, and removes the publisher pay wall for access to this information.
What research and development partnerships will the Gates MRI pursue?

Focused on serving as a convener and connector in the research and development community, the Gates MRI will collaborate with foundation product development partners, academia, pharmaceutical and biotech companies, LMIC manufacturers and non-profit organizations on upstream and downstream activities. We will establish partnerships that leverage assets, capabilities and expertise in order to accelerate product development for our disease areas of interest. The Gates MRI actively and continuously engages directly in the conduct of medical research in conjunction with one or more hospitals for the purpose of addressing major causes of illness and death in LMIC.

Will the Gates MRI only take product development to phase 2? Assuming a viable candidate is developed, how will the Gates MRI identify partners to bring products through to commercialization?

The Gates MRI will focus on translational product development, (defined as preclinical candidate selection to human/clinical proof of concept in the target population). Once a candidate has achieved human proof of concept, the plan is to partner the program with an organization that has late-stage development and commercial expertise. Late-stage development partners may include non-profit product development partners, LMIC manufacturers, and pharmaceutical companies.

How will the Gates MRI ensure that products developed by the organization will be made available to the world's poorest populations at an acceptable volume and affordable price?

The Gates MRI will adhere to the foundation's Global Access policy. Organizations that partner with the foundation agree to Global Access, which requires that the knowledge and information gained from a funded project will be promptly and broadly disseminated, and that funded developments will be made available and accessible at an affordable price to people in need within LMIC.

CAREERS

Join Our Team

The Gates MRI is a diverse group of passionate change-makers, creative fixers and relentless advocates. We are committed to saving lives by improving the pace and predictability of translational medicine in global health. We will relentlessly seek out innovative strategies to develop the best drugs, biologics, and vaccines to fight some of the toughest, most complex disease problems in the world. Our focus is translating findings from basic science into potential solutions that will fill the product pipeline for malaria, tuberculosis, and enteric and diarrheal diseases to start.

Our culture thrives on our five mantras:

  • Urgency: Strive every day to do better than your last best accomplishment.
  • Collaboration: Solving the world’s most complex disease burdens is a team effort.
  • Innovation: Uncover new methods, approaches and solutions to achieve unprecedented results.
  • Rigor: Follow the science with passion and perseverance.
  • Courage: Pursue progress boldly to deliver on our bottom line: lives saved.

We are bringing together top talent from diverse scientific backgrounds to work across a range of disease areas and modalities, building upon the best work being done in scientific discovery, constantly pushing the envelope, and embracing new methodologies.

The Gates MRI aims to use quantitative sciences; to develop strong biomarker strategies upfront, and understand production issues early on to drive greater rigor in global health clinical research, enabling potentially faster development of products for diseases of the poorest. We will seek to publish our learnings, so that they will be available to all research and development communities through our commitment to open access.

If you share our belief that all lives have equal value, and that science and technology can change lives for the better, we would love to connect with you. Please review our Current Opportunities through the link below and apply directly for consideration: LinkedIn or submit your resume to human resources at [email protected].

Gates MRI

News

REFERENCES
1. Whitfield J. Portrait of a serial killer. Nature. 2002. doi:10.1038/news021001-6.
2. Global Health Observatory (GHO) data: Tuberculosis (TB). World Health Organization Web site. http://www.who.int/gho/tb/en/. Accessed May, 2018.
3. Global Diarrhea Burden. Centers for Disease Control and Prevention Web site. https://www.cdc.gov/healthywater/global/diarrhea-burden.html. Updated December 17, 2015. Accessed May, 2018.
4. WHO Diarrhoeal disease fact sheet, updated May 2017; WHO Malaria Policy and Advisory Committee Meeting Report 2018; WHO Global Tuberculosis Report 2017.